ClinicalTrials.gg
CompletedNCT01010776Updated Nov 20, 2013Results posted

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

A Phase 4 interventional study of Paliperidone Extended Release (ER) in Schizophrenia, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 11 sites in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-11-20.

Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
223
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
49th of 115
223 · median 178
Started
2008
with 12 others
Phase 4
42 of 115
5 open now
Registered
50th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 49th largest by enrollment, is one of 13 that started in 2008, is one of 42 in phase 4, and was the 50th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate effectiveness, tolerability (how well a participant can stand a particular medicine or treatment), and safety of flexible-dose of paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self), previously taking risperidone (an antipsychotic), but who are not satisfied with their treatment.

Read the detailed description

This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center (when more than 1 hospital or medical school team work on a medical research study), non-randomized, single-arm study of paliperidone ER in participants previously treated with risperidone with poor response. The study will consist of 2 phases: a main phase of 6 months and an extension phase of another 6 months. The total duration of the study will be 12 months. All participants will receive an oral (having to do with the mouth) daily dose of paliperidone ER in flexible dosage (in the range of 3-12 milligram [mg]: 3 mg, 6 mg, 9 mg, or 12 mg) according to Investigator's discretion. Efficacy and safety of participants will primarily be evaluated by Positive and Negative Syndrome Scale (PANSS) and Extrapyramidal Symptoms Rating Scale (ESRS), respectively. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants must be (after the time in life when a woman stops having a menstrual period) or surgically sterile or if sexually active, practicing an effective method of (e.g., oral contraceptive, intrauterine device [IUD - an intrauterine device made of plastic and/or copper that is inserted into the womb [uterus] by way of the vaginal canal to used to prevent pregnancy], diaphragm with spermicide [agent that kills spermatozoa] or condom [cover worn over the penis during sexual intercourse to prevent infection or pregnancy] with spermicide) throughout the study and have a negative serum beta - Human Chorionic Gonadotropin (HCG) pregnancy test at screening
  • Participants on oral monotherapy (treatment with a single drug) with risperidone in a regimen within the daily dosage recommended by the package insert and adhering to the prescribed risperidone regimen for at least 30 days before entering the study
  • Participants with partial response to the current risperidone regimen (persistent symptoms or unstable clinical condition) or presence of unbearable side effects
  • Potential Participants switching to another atypical antipsychotic due to their clinical response and/or side effects profile.

Exclusion criteria

Exclusion Criteria:

  • Participants with past or current history of psychiatric disease other than schizophrenia according to (DSM)-IV
  • Participants with concomitant (given at the same time) severe (very serious, life threatening) medical or neurological disorder or risk of suicide
  • Participants previously using clozapine
  • Participants with a history of previous non-responsiveness to oral antipsychotic treatment
  • Pregnant or breast-feeding female participants
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Paliperidone Extended Release (ER)

    Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.

    Drug: Paliperidone Extended Release (ER)

Interventions

  • Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Week 26

  2. Change From Baseline in PANSS Total Score at Week 52 - Main Phase Plus Extension Phase

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase

    Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 26

  2. Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase Plus Extension Phase

    Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Week 52

  3. Change From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13 and 26 - Main Phase

    The PANSS positive subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS negative subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline, Week 4, 8, 13 and 26

  4. Change From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

    The PANSS Positive Subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52

  5. Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 4, 8, 13 and 26 - Main Phase

    The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.

    Time frame: Baseline, Week 4, 8, 13 and 26

  6. Change From Baseline in PSP Scale Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

    The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.

    Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52

  7. Change From Baseline in Pittsburg Sleep Quality Index (PSQI) Score at Week 4, 8, 13 and 26 - Main Phase

    The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.

    Time frame: Baseline, Week 4, 8, 13 and 26

  8. Change From Baseline PSQI Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

    The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.

    Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52

  9. Number of Participants With Clinical Global Impression-Severity (CGI-S) Score - Main Phase

    The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Baseline, Week 4, 8, 13 and 26

  10. Number of Participants With Clinical Global Impression-Severity (CGI-S) Score - Extension Phase

    The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Week 39 and 52

  11. Percentage of Participants With Treatment Satisfaction - Main Phase

    Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.

    Time frame: Baseline, Week 4, 8, 13 and 26

  12. Percentage of Participants With Treatment Satisfaction-Main Phase Plus Extension Phase

    Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.

    Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52

  13. 36-Item Short-Form Health Survey (SF-36) Score - Main Phase

    The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.

    Time frame: Baseline and Week 26

  14. 36-Item Short-Form Health Survey (SF-36) Score - Main Phase Plus Extension Phase

    The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.

    Time frame: Baseline and Week 52

Other outcomes

  1. Change From Baseline in Extrapyradimal Symptoms Rating Scale (ESRS) Total Score at Week 4, 8, 13 and 26 - Main Phase

    An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.

    Time frame: Baseline, Week 4, 8, 13 and 26

  2. Change From Baseline in ESRS Total Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

    An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.

    Time frame: Baseline, Week 4, 8, 13, 26, 39 and 52

07

Results

Posted Nov 20, 2013

Participant flow

Main Phase
Participant flow — Main Phase
MilestonePaliperidone Extended Release (ER)
Started223
Treated218
Completed174
Not completed49
Withdrew: Withdrawal by subject14
Withdrew: Lack of efficacy8
Withdrew: Adverse event7
Withdrew: Lost to follow-up6
Withdrew: Non-compliance to study medication5
Withdrew: Selection failure2
Withdrew: Inform consent withdrawal1
Withdrew: Other1
Withdrew: Did not received study medication5
In-Between Main Phase & Extension Phase
Participant flow — In-Between Main Phase & Extension Phase
MilestonePaliperidone Extended Release (ER)
Started174
Completed159
Not completed15
Withdrew: Extension phase was optional15
Extension Phase
Participant flow — Extension Phase
MilestonePaliperidone Extended Release (ER)
Started159
Completed156
Not completed3
Withdrew: Other3

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase
Units on a scalePaliperidone Extended Release (ER) - Main Phase
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase-22.9 ± 20.1
PrimaryChange From Baseline in PANSS Total Score at Week 52 - Main Phase Plus Extension Phase

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Total Score at Week 52 - Main Phase Plus Extension Phase
Units on a scalePaliperidone (ER) - Main Phase Plus Extension Phase
Baseline93.25 ± 11.6
Change at Week 52-26.4 ± 17.5
SecondaryPercentage of Participants With Treatment Response in PANSS Total Score - Main Phase

Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase
Percentage of participantsPaliperidone ER-Main Phase
Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase60.1 (53.2 to 66.7)
SecondaryPercentage of Participants With Treatment Response in PANSS Total Score - Main Phase Plus Extension Phase

Participants with response in PANSS total score was defined as participants with greater than or equal to 20 percent reduction in PANSS total score from Baseline. The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase Plus Extension Phase
Percentage of participantsPaliperidone ER-Main Phase Plus Extension Phase
Percentage of Participants With Treatment Response in PANSS Total Score - Main Phase Plus Extension Phase71.1 (63.4 to 78.0)
SecondaryChange From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13 and 26 - Main Phase

The PANSS positive subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS negative subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline, Week 4, 8, 13 and 26
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13 and 26 - Main Phase
Units on a scalePaliperidone ER-Main Phase
Change at Week 4: PANSS positive subscale (n=201)-3.6 ± 4.8
Change at Week 4: PANSS negative subscale (n=201)-3.6 ± 4.8
Change at Week 8: PANSS positive subscale (n=191)-5.0 ± 5.8
Change at Week 8: PANSS negative subscale (n=191)-5.0 ± 5.8
Change at Week 13: PANSS positive subscale (n=182)-5.9 ± 5.8
Change at Week 13: PANSS negative subscale (n=182)-5.9 ± 5.8
Change at Week 26: PANSS positive subscale (n=203)-5.9 ± 6.2
Change at Week 26: PANSS negative subscale (n=203)-5.9 ± 6.2
SecondaryChange From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

The PANSS Positive Subscale assesses 7 positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology). The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline, Week 4, 8, 13, 26, 39 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative PANSS Subscales Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
Units on a scalePaliperidone ER-Main Phase Plus Extension Phase
Baseline: PANSS positive subscale (n=159)26.65 ± 6.20
Baseline: PANSS negative subscale (n=159)19.25 ± 5.86
Change at Week 4: PANSS positive subscale (n=159)-3.4 ± 4.4
Change at Week 4: PANSS negative subscale (n=159)-3.4 ± 4.4
Change at Week 8: PANSS positive subscale (n=159)-5.4 ± 5.1
Change at Week 8: PANSS negative subscale (n=159)-5.4 ± 5.1
Change at Week 13: PANSS positive subscale (n=159)-5.9 ± 5.7
Change at Week 13: PANSS negative subscale (n=159)-5.9 ± 5.7
Change at Week 26: PANSS positive subscale (n=159)-6.8 ± 5.5
Change at Week 26: PANSS negative subscale (n=159)-6.8 ± 5.5
Change at Week 39: PANSS positive subcale (n=152)-7.3 ± 5.9
Change at Week 39: PANSS negative subscale (n=152)-7.3 ± 5.9
Change at Week 52: PANSS positive subscale (n=154)-7.5 ± 6.1
Change at Week 52: PANSS negative subscale (n=154)-7.5 ± 6.1
SecondaryChange From Baseline in Personal and Social Performance (PSP) Scale Score at Week 4, 8, 13 and 26 - Main Phase

The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.

Time frame:
Baseline, Week 4, 8, 13 and 26
Reported as:
Mean · Units on a scale
Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 4, 8, 13 and 26 - Main Phase
Units on a scalePaliperidone ER-Main Phase
Change at Week 4 (n=201)5.7 ± 11.7
Change at Week 8 (n=191)8.3 ± 12.8
Change at Week 13 (n=182)9.9 ± 14.8
Change at Week 26 (n=204)10.4 ± 14.9
SecondaryChange From Baseline in PSP Scale Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

The PSP scale evaluates the dysfunction degree exhibited by the participants, regarding 4 behavioral domains: useful social activities, personal and social relations, self-care and agitated and aggressive behavior. Each domain were assessed on a 6-point scale (0=absent to 5=very severe). A transformed score from 1 to 100 is generated from the raw score based on the clinical interpretation of the scores generated in the 4 areas of functioning, with a higher transformed score indicating better function.

Time frame:
Baseline, Week 4, 8, 13, 26, 39 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in PSP Scale Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
Units on a scalePaliperidone ER-Main Phase Plus Extension Phase
Baseline (n=159)45.17 ± 12.84
Change at Week 4 (n=159)5.3 ± 9.6
Change at Week 8 (n=159)9.0 ± 12.6
Change at Week 13 (n=159)9.7 ± 14.4
Change at Week 26 (n=159)12.0 ± 12.7
Change at Week 39 (n=151)12.6 ± 14.2
Change at Week 52 (n=155)14.6 ± 14.9
SecondaryChange From Baseline in Pittsburg Sleep Quality Index (PSQI) Score at Week 4, 8, 13 and 26 - Main Phase

The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.

Time frame:
Baseline, Week 4, 8, 13 and 26
Reported as:
Mean · Units on a scale
Change From Baseline in Pittsburg Sleep Quality Index (PSQI) Score at Week 4, 8, 13 and 26 - Main Phase
Units on a scalePaliperidone ER-Main Phase
Baseline (n=198)6.7 ± 4.1
Change at Week 4 (n=174)-1.0 ± 3.5
Change at Week 8 (n=162)-1.2 ± 3.5
Change at Week 13 (n=156)-1.5 ± 3.3
Change at Week 26 (n=174)-1.4 ± 3.7
SecondaryChange From Baseline PSQI Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

The PSQI evaluates sleep behavior by means of 7 components: sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of sleep medication and daytime dysfunction. The sum of the 7 component scores produces a global score of subjective sleep quality that varies from 0 to 21, with higher scores indicating worse sleep quality.

Time frame:
Baseline, Week 4, 8, 13, 26, 39 and 52
Reported as:
Mean · Units on a scale
Change From Baseline PSQI Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
Units on a scalePaliperidone ER-Main Phase Plus Extension Phase
Baseline (n=148)6.4 ± 4.1
Change at Week 4 (n=140)-1.0 ± 3.6
Change at Week 8 (n=136)-1.3 ± 3.2
Change at Week 13 (137)-1.5 ± 3.2
Change at Week 26 (n=135)-1.4 ± 3.5
Change at Week 39 (n=133)-1.9 ± 3.9
Change at Week 52 (n=133)-1.9 ± 3.4
SecondaryNumber of Participants With Clinical Global Impression-Severity (CGI-S) Score - Main Phase

The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Baseline, Week 4, 8, 13 and 26
Reported as:
Number · Participants
Number of Participants With Clinical Global Impression-Severity (CGI-S) Score - Main Phase
ParticipantsPaliperidone ER-Main Phase
Baseline: Borderline (n=213)2
Baseline: Slightly ill (n=213)4
Baseline: Moderately ill (n=213)52
Baseline: Markedly ill (n=213)114
Baseline: Severely ill (n=213)40
Baseline: Extremely ill (n=213)1
Week 4: Borderline (n=201)4
Week 4: Slightly ill (n=201)25
Week 4: Moderately ill (n=201)87
Week 4: Markedly ill (n=201)61
Week 4: Severely ill (n=201)24
Week 8: Borderline (n=191)5
Week 8: Slightly ill (n=191)35
Week 8: Moderately ill (n=191)80
Week 8: Markedly ill (n=191)56
Week 8: Severely ill (n=191)15
Week 8: extremely ill (n=191)0
Week 13: Normal, without any disease (n=182)2
Week 13: Borderline (n=182)7
Week 13: Slightly ill (n=182)41
Week 13: Moderately ill (n=182)73
Week 13: Markedly ill (n=182)47
Week 13: Severly ill (n=182)12
Week 26: Normal without any disease (n=204)3
Week 26: Borderline (n=204)16
Week 26: Slightly ill (n=204)48
Week 26: Moderately ill (n=204)70
Week 26: Markedely ill (n=204)48
Week 26: Severely ill (n=204)19
SecondaryNumber of Participants With Clinical Global Impression-Severity (CGI-S) Score - Extension Phase

The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.The categories included in the scale are normal, without any disease, borderline, slightly ill, moderately ill, markedly ill, severely ill and extremely ill. A rating of 1="Normal, not at all ill" and a rating of 7 ="Among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Week 39 and 52
Reported as:
Number · Participants
Number of Participants With Clinical Global Impression-Severity (CGI-S) Score - Extension Phase
ParticipantsPaliperidone ER - Extension Phase
Week 39: Normal without any disease (n=152)2
Week 39: Borderline (n=152)22
Week 39: Slightly ill (n=152)41
Week 39: Moderately ill (n=152)55
Week 39: Markedely ill (n=152)22
Week 39: Severely ill (n=152)10
Week 52: Borderline (n=155)23
Week 52: Slightly ill (n=155)37
Week 52: Moderately ill (n=155)58
Week 52: Markedely ill (n=155)24
Week 52: Severely ill (n=155)10
SecondaryPercentage of Participants With Treatment Satisfaction - Main Phase

Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.

Time frame:
Baseline, Week 4, 8, 13 and 26
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment Satisfaction - Main Phase
Percentage of ParticipantsPaliperidone ER - Main Phase
Baseline: Very good (n=213)11.7
Baseline: Good (n=213)38.5
Baseline: Moderate (n=213)34.3
Baseline: Bad (n=213)12.7
Baseline: Very bad (n=213)2.8
Week 4: Very good (n=200)29.5
Week 4: Good (n=200)52.5
Week 4: Moderate (n=200)16.5
Week 4: Bad (n=200)1.0
Week 4: Very bad (n=200)0.5
Week 8: Very good (n=190)33.7
Week 8: Good (n=190)48.9
Week 8: Moderate (n=190)13.7
Week 8: Bad (n=190)3.7
Week 13: Very good (n=182)37.4
Week 13: Good (n=182)46.2
Week 13: Moderate (n=182)12.1
Week 13: Bad (n=182)3.8
Week 13: Very bad (n=182)0.5
Week 26: Very good (n=204)36.3
Week 26: Good (n=204)46.1
Week 26: Moderate (n=204)10.8
Week 26: Bad (n=204)4.4
Week 26: Very bad (n=204)2.5
SecondaryPercentage of Participants With Treatment Satisfaction-Main Phase Plus Extension Phase

Participant's response regarding satisfaction with the treatment were recorded. A 5-point evaluation scale was used to evaluate participant satisfaction: very good, good, moderate, bad and very bad.

Time frame:
Baseline, Week 4, 8, 13, 26, 39 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Satisfaction-Main Phase Plus Extension Phase
Percentage of participantsPaliperidone ER-Main Phase Plus Extension Phase
Baseline: Very good (n=159)13.2
Baseline: Good (n=159)40.9
Baseline: Moderate (n=159)32.1
Baseline: Bad (n=159)11.3
Baseline: Very bad (n=159)2.5
Week 4: Very good (n=159)31.4
Week 4: Good (n=159)54.1
Week 4: Moderate (n=159)13.8
Week 4: Very bad (n=159)0.6
Week 8: Very good (n=159)37.1
Week 8: Moderate (n=159)11.3
Week 8: Bad (n=159)3.1
Week 13: Very good (n=159)39.0
Week 13: Good (n=159)46.5
Week 13: Moderate (n=159)10.1
Week 13: Bad (n=159)3.8
Week 13: Very bad (n=159)0.6
Week 26: Very good (n=159)41.5
Week 26: Good (n=159)50.9
Week 26: Moderate (n=159)6.9
Week 26: Very bad (n=159)0.6
Week 39: Very good (n=152)38.8
Week 39: Good (n=152)51.3
Week 39: Moderate (n=152)7.2
Week 39: Bad (n=152)2.0
Week 39: Very bad (n=152)0.7
Week 52: Very good (n=155)41.3
Week 52: Good (n=155)43.2
Week 52: Moderate (n=155)12.9
Week 52: Bad (n=155)2.6
Secondary36-Item Short-Form Health Survey (SF-36) Score - Main Phase

The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.

Time frame:
Baseline and Week 26
Reported as:
Mean · Units on a scale
36-Item Short-Form Health Survey (SF-36) Score - Main Phase
Units on a scalePaliperidone ER- Main Phase
Baseline: Physical component summary47.9 ± 8.8
Baseline: Mental component summary35.9 ± 8.5
Week 26: Physical component summary48.4 ± 7.6
Week 26: Mental component summary38.3 ± 8.0
Secondary36-Item Short-Form Health Survey (SF-36) Score - Main Phase Plus Extension Phase

The SF-36 is designed to assess the health status of participants. The SF-36 includes 1 multi-item scale measuring physical health component and mental health component. Physical health component includes physical functioning, role limitations due to physical health, pain and general health. Mental health component includes role limitations due to emotional problems, energy/fatigue, emotional well being and social functioning. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. The score for a component (physical or mental) is an average of the individual item scores. Each component is scored on a scale of 1 to 100, where 100=highest level of functioning.

Time frame:
Baseline and Week 52
Reported as:
Mean · Units on a scale
36-Item Short-Form Health Survey (SF-36) Score - Main Phase Plus Extension Phase
Units on a scalePaliperidone ER-Main Phase Plus Extension Phase
Baseline: Physical component summary48.7 ± 8.6
Baseline: Mental component summary35.7 ± 8.5
Week 52: Physical component summary48.8 ± 7.6
Week 52: Mental component summary38.5 ± 8.4
Other pre-specifiedChange From Baseline in Extrapyradimal Symptoms Rating Scale (ESRS) Total Score at Week 4, 8, 13 and 26 - Main Phase

An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.

Time frame:
Baseline, Week 4, 8, 13 and 26
Reported as:
Mean · Units on a scale
Change From Baseline in Extrapyradimal Symptoms Rating Scale (ESRS) Total Score at Week 4, 8, 13 and 26 - Main Phase
Units on a scalePaliperidone ER - Main Phase
Baseline (n=215)1.30 ± 1.99
Change at Week 4 (n=201)-0.40 ± 1.23
Change at Week 8 (n=189)-0.45 ± 1.47
Change at Week 13 (n=182)-0.63 ± 1.76
Change at Week 26 (n=201)-0.6 ± 1.71
Other pre-specifiedChange From Baseline in ESRS Total Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase

An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.

Time frame:
Baseline, Week 4, 8, 13, 26, 39 and 52
Reported as:
Mean · Units on a scale
Change From Baseline in ESRS Total Score at Week 4, 8, 13, 26, 39 and 52 - Main Phase Plus Extension Phase
Units on a scalePaliperidone ER-Main Plus Extension Phase
Baseline (n=159)1.41 ± 2.14
Change at Week 4 (n=159)-0.51 ± 1.31
Change at Week 8 (n=159)-0.49 ± 1.56
Change at Week 13 (n=159)-0.68 ± 1.85
Change at Week 26 (n=158)-0.77 ± 1.87
Change at Week 39 (n=151)-0.81 ± 1.97
Change at Week 52 (n=154)-0.75 ± 1.94

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone ER - Main Phase—14/215 (6.5%)144/215 (67%)
Paliperidone ER - Extension Phase—3/159 (1.9%)70/159 (44%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPaliperidone ER - Main PhasePaliperidone ER - Extension Phase
Psychotic disorder NOSPsychiatric disorders5/2150/159
Schizophrenia NOSPsychiatric disorders2/2151/159
HospitalizationSurgical and medical procedures2/2150/159
Nasal septum deviationRespiratory, thoracic and mediastinal disorders0/2151/159
CholecystectomySurgical and medical procedures0/2151/159
Pregnancy NOSPregnancy, puerperium and perinatal conditions0/2151/159
HypokalemiaMetabolism and nutrition disorders1/2150/159
HyponatremiaMetabolism and nutrition disorders1/2150/159
Depressed moodPsychiatric disorders1/2150/159
Psychomotor agitationPsychiatric disorders1/2150/159
Most frequent other events
Showing 10 of 105
Most frequent other events
EventPaliperidone ER - Main PhasePaliperidone ER - Extension Phase
InsomniaPsychiatric disorders32/21514/159
Weight increasedInvestigations23/21520/159
AnxietyPsychiatric disorders23/2154/159
SomnolenceNervous system disorders13/2154/159
HeadacheNervous system disorders13/2154/159
AgitationPsychiatric disorders12/2150/159
DepressionPsychiatric disorders8/2157/159
AkathisiaNervous system disorders8/2155/159
Psychomotor hyperactivityNervous system disorders8/2150/159
Psychotic disorder NOSPsychiatric disorders7/2150/159

Baseline characteristics

Age Continuous
Age Continuous(Years)Paliperidone ER - Main Phase Plus Extension Phase
Mean37.87 ± 11.01
Age, Customized
Age, Customized(Participants)Paliperidone ER - Main Phase Plus Extension Phase
18-21 years14
22-29 years50
30-39 years51
40-49 years67
50-60 years35
61-69 years1
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone ER - Main Phase Plus Extension Phase
Female79
Male139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Paliperidone ER - Main Phase Plus Extension Phase
White/Caucasian120
Black52
Oriental3
Mulatto9
Brown34
Positive and Negative Syndrome Scale (PANSS) Total Score
Positive and Negative Syndrome Scale (PANSS) Total Score(Units on a scale)Paliperidone ER - Main Phase Plus Extension Phase
Mean94.49 ± 12.38
Positive and Negative PANSS Subscales Score
Positive and Negative PANSS Subscales Score(Units on a scale)Paliperidone ER - Main Phase Plus Extension Phase
Positive PANSS Subscale Score27.37 ± 6.48
Negative PANSS Subscale Score19.76 ± 5.79
Personal and Social Performance (PSP) Scale Score
Personal and Social Performance (PSP) Scale Score(Units on a scale)Paliperidone ER - Main Phase Plus Extension Phase
Mean44.39 ± 13.11
Pittsburg Sleep Quality Index (PSQI)
Pittsburg Sleep Quality Index (PSQI)(Units on a scale)Paliperidone ER - Main Phase Plus Extension Phase
Mean6.7 ± 4.1
08

Study locations

11 sites
  • Belo Horizonte, Brazil
  • Criciúma, Brazil
  • Curitiba, Brazil
  • Goiânia, Brazil
  • Itapira, Brazil
  • Marília, Brazil
  • Rio De Janeiro, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Sorocaba, Brazil
  • São Paulo, Brazil
09

References and documents

Publications

  • Gattaz WF, Campos JA, Lacerda AL, Henna E, Ruschel SI, Bressan RA, de Oliveira IR, Rocha FL, Grabowski HM, Sacomani E Jr, Louza MR, Quevedo J, Elkis H, Zorzetto Filho D, Perico Cde A, Lawson FL, Appolinario JC. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Curr Med Res Opin. 2014 Apr;30(4):695-709. doi: 10.1185/03007995.2013.869201. Epub 2013 Dec 16. PubMed 24289141 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2009
First posted
Nov 10, 2009
Start
Feb 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Nov 20, 2013
Last update
Nov 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01010776
Responsible party
Sponsor
First posted
Nov 10, 2009
Start date
Feb 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Nov 20, 2013
Last update
Nov 20, 2013

Study contacts

Janssen-Cilag Farmaceutica Ltda. Clinical Trial
study director · Janssen-Cilag Farmaceutica Ltda.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion